ClinicalTrials.gg
RecruitingNCT07732309ATTRACTUpdated Oct 28, 2026

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

A Phase 1 interventional study of ATG-201 in Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) and Sjogren's Disease, sponsored by Antengene Biologics Limited. Recruiting at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Antengene Biologics Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
149
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
57th of 245
149 · median 36
Started
2026
with 55 others
Phase 1
109 of 266
85 open now
Primary completion
2028-12
later than 167 of 190 live
Registered
262nd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 57th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 167 of the 190 other live ones, and was the 262nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

162 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This is a phase I, open-label study of ATG-201 in participants with autoimmune diseases.

Read the detailed description

This is a phase I, open-label, first-in-human clinical trial to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of ATG-201 in participants with autoimmune diseases. The study will be conducted in 2 parts: Dose Escalation (Part I) and Dose Expansion (Part II).

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Systemic Sclerosis (SSc)
  • Sjogren's Disease
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who give consent to this study participation and sign form.
  2. Participants at least 18 years of age inclusive at screening visit.
  3. Must be able to adhere to the study visit schedule and other protocol .requirements.
  4. Female of must agree to use adequate measures from 28 days before starting study treatment to until 48 weeks after last dose of treatment, not breastfeeding, and have a negative serum pregnancy test at screening.
  5. Male participants must agree to use an effective barrier method of contraception during sexual contact with a female of childbearing potential during screening and throughout the study until 48 weeks after the final dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Intolerance or allergy to the product, or to any component thereof, or to any concomitant medications that may be used in the study (e.g., tocilizumab).
  2. Presence of central nervous system disorders of either or non-autoimmune etiology, including but not limited to: epilepsy, psychotic disorders, organic brain syndrome, cerebrovascular accident, encephalitis, or central nervous system vasculitis.
  3. Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening.
  4. Severe (requiring oxygen support) or rapidly progressing interstitial lung disease.
  5. Uncontrolled other diseases: history or clinical evidence of active significant acute or chronic diseases (i.e., cardiovascular, pulmonary, untreated hypertension, anemia, gastrointestinal, hepatic, renal, neurological, cancer, or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.
  6. History of a major organ transplant (e.g. heart, lung, renal, liver) or hematopoietic stem cell/marrow transplant.
  7. Have a planned surgical procedure, or a history of any other medical disease, or laboratory abnormalities, or conditions which would make the participant (in the opinion of the investigator) unsuitable for the study.
  8. Received intravenous immunoglobulin, plasmapheresis, hemodialysis, intravenous cyclophosphamide, or high dose prednisone and its equivalents (>60 mg/day) within 2 months prior to screening.
  9. Live or attenuated vaccine within 28 days prior to screening or during screening.
  10. Participants who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months or who, in the investigator's opinion, pose a significant suicide risk.
  11. The participant has an abnormality on 12-lead at screening which is in the opinion of the investigator, and which could confound the results of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
149 participants (estimated)

Study arms

  • Experimental
    ATG-201

    This is a phase I, open-label, first-in-human clinical trial to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of ATG-201 in participants with autoimmune diseases. The study will be conducted in 2 parts: Dose Escalation (Part I) and Dose Expansion (Part II). Part I (Dose Escalation) A total of 9 dose levels is preset In Part II (Dose Expansion), the OBD(s) will be further explored and evaluated

    Drug: ATG-201

Interventions

  • DrugATG-201

    ATG-201 is a recombinant, human IgG1-like TCE that simultaneously binds to human CD3 and CD19.

06

What researchers measure

Primary outcomes

  1. Safety and TolerabilitySafety and Tolerability

    Incidence and severity of adverse events (AEs), CRS.

    Time frame: 48 weeks

Other outcomes

  1. To evaluate the PK of ATG-201

    Serum concentrations of ATG-201

    Time frame: 48 weeks

  2. Detection of anti-drug antibodies

    Detection of anti-drug antibodies

    Time frame: 48 weeks

  3. Change from baseline in B lymphocyte cell numbers in peripheral bloo

    B lymphocyte cell numbers and change from baseline in peripheral blood

    Time frame: 48 weeks

07

Study locations

1 of 22 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
    Not yet recruiting
    • Changhao Xie · Contact
    • Huan Zhou · Contact
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui, China
    Not yet recruiting
    • Zhu Chen · Contact
  • Peking University People's Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Zhanguo Li · Contact
    • Tian Liu · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Not yet recruiting
    • Guixiu Shi · Contact
  • Nanfang Hospital of Southern Medical Universit
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Min Yang · Contact
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen Universit
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Lie Dai · Contact
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Qingping Liu · Contact
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yujin Ye · Contact
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yunfeng Pan · Contact
    • Jian Sun · Contact
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Not yet recruiting
    • Xiaofei Shi · Contact
    • Cai'e Wang · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Not yet recruiting
    • Shengyun Liu · Contact
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Qiubai Li · Contact
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Not yet recruiting
    • Hui Luo · Contact
  • Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School
    Nanjing, Jiangsu, China
    Not yet recruiting
    • Lingyun Sun · Contact
  • Nuclear Industry General Hospital
    Suzhou, Jiangsu, China
    Not yet recruiting
    • Zhichun Liu · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Not yet recruiting
    • Qiang Shu · Contact
  • Linyi People's Hospital
    Linyi, Shandong, China
    Not yet recruiting
    • Peng Yan · Contact
    • Guoying Cao · Contact
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Yu Xue · Contact
    • Guoying Cao · Contact
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Xiaobing Wang · Contact
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Not yet recruiting
    • Hongyan Wen · Contact
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi, China
    Not yet recruiting
    • Xueyi Li · Contact
    • Hui Guo · Contact
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Jing Xue · Contact
    • Bo Jiang · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 26 months is close to that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 28, 2026
StartActual
Sep 26, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jun 1, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
22 sites changed recruiting status (21 now not yet recruiting, 1 now recruiting)
Show 22 sites
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
  • Peking University People's Hospital · Beijing, Chinano status→Recruiting
  • The First Affiliated Hospital of Xiamen University · Xiamen, Chinano status→Not yet recruiting
  • Nanfang Hospital of Southern Medical Universit · Guangzhou, Chinano status→Not yet recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen Universit · Guangzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine · Guangzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • The Third Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
  • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School · Nanjing, Chinano status→Not yet recruiting
  • Nuclear Industry General Hospital · Suzhou, Chinano status→Not yet recruiting
  • Qilu Hospital of Shandong University · Jinan, Chinano status→Not yet recruiting
  • Linyi People's Hospital · Linyi, Chinano status→Not yet recruiting
  • Huashan Hospital Affiliated to Fudan University · Shanghai, Chinano status→Not yet recruiting
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
  • The First Hospital of Shanxi Medical University · Taiyuan, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University · Xi’an, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
Oct 28, 2026
Start date
Sep 1, 2026→Sep 26, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    22 sites changed recruiting status (21 now not yet recruiting, 1 now recruiting)
    Show 22 sites
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
    • Peking University People's Hospital · Beijing, Chinano status→Recruiting
    • The First Affiliated Hospital of Xiamen University · Xiamen, Chinano status→Not yet recruiting
    • Nanfang Hospital of Southern Medical Universit · Guangzhou, Chinano status→Not yet recruiting
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen Universit · Guangzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Guangzhou University of Chinese Medicine · Guangzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • The Third Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
    • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School · Nanjing, Chinano status→Not yet recruiting
    • Nuclear Industry General Hospital · Suzhou, Chinano status→Not yet recruiting
    • Qilu Hospital of Shandong University · Jinan, Chinano status→Not yet recruiting
    • Linyi People's Hospital · Linyi, Chinano status→Not yet recruiting
    • Huashan Hospital Affiliated to Fudan University · Shanghai, Chinano status→Not yet recruiting
    • Renji Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Chinano status→Not yet recruiting
    • The First Hospital of Shanxi Medical University · Taiyuan, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Xi'an Jiaotong University · Xi’an, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
    Start date Sep 1, 2026→Sep 26, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07732309
Lead sponsor
Antengene Biologics Limited
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Sep 26, 2026
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Iris Li
Contact
iris.li@antengene.com
021-32501095

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion